Management for patients with advanced T4 epidermoid carcinoma of the esophagus

Liang Shun Wang, Kwan Hwa Chi, Maw Hwa Hu, Huei Jyh Fahn, Min Hsiung Huang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Available data concerning the treatment of patients with advanced T4 esophageal carcinoma are limited. A consecutive series of 42 patients with advanced T4M0 epidermoid carcinoma of the esophagus were studied from June 1987 to July 1992. The aim of this study was to evaluate the efficacy of various therapeutic modalities, and further evaluate the therapeutic options. The various therapeutic modalities included the following: Group 1, feeding jejunostomy or endoesophageal intubation, 6 patients; Group II, palliative subtotal esophagectomy only, 8 patients; Group III, bypass procedures without tumor resection, 9 patients; Group IV, nutritional support and then treatment with irradiation (n = 8) or concurrent radio-chemotherapy (n = 4), 12 patients; Group V, subtotal esophagectomy, followed by aggressive concurrent radiochemotherapy, 7 patients. The total prescribed irradiation dose was 60 Gy (10 Gy/5 fractions/week). A combination regimen of chemotherapy consisted of cisplatin, 5-fluorouracil, and leucovorin (PFL regimen). For the patients undergoing esophagectomy or bypass procedures (n = 24), the rates of operative complication and mortality were 45.8% and 25%, respectively. Side effects of adjuvant therapy (n = 24) consisted of main airway irritation (100%), mucositis or gastrointestinal symptoms (83.3%), hematologic toxicity (79.2%), esophagitis or gastric ulcer (62.5%), alopecia (37.5%), and pneumonia (20.8%). The mortality due to toxicity of adjuvant therapy was 21.1% (4/19 patients). The mean survival times for each of the different groups was 1.9 ± 0.5 months for Group I, 4.8 ± 1.6 months for Group II, 5.2 ± 1.2 months for Group III, 7.3 ± 2.0 months for Group IV, and 20.3 ± 2.5 months for Group V, respectively. Compared with patients of Groups I-IV, the Group V patients had a significantly superior one-year survival rate (P <0.01). Our results demonstrated that esophagectomy followed by concurrent irradiation and PFL combination chemotherapy may provide a significant improvement in the quality of life and survival for appropriate patients with advanced T4M0 epidermoid carcinoma of the esophagus. Furthermore, more than one cycle of PFL regimen chemotherapy may result in a better prognosis. During the performance of such an aggressive treatment, the utmost care must be taken with the patient's nutrition and to prevent pulmonary complications.

Original languageEnglish
Pages (from-to)22-29
Number of pages8
JournalJournal of Surgical Oncology
Volume62
Issue number1
DOIs
Publication statusPublished - May 1996
Externally publishedYes

Fingerprint

Esophagus
Squamous Cell Carcinoma
Esophagectomy
Therapeutics
Combination Drug Therapy
Survival Rate
Jejunostomy
Drug Therapy
Mucositis
Leucovorin
Nutritional Support
Esophagitis
Mortality
Alopecia
Chemoradiotherapy
Stomach Ulcer
Radio
Intubation
Fluorouracil
Cisplatin

Keywords

  • esophageal carcinoma
  • esophagectomy
  • radiochemotherapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Management for patients with advanced T4 epidermoid carcinoma of the esophagus. / Wang, Liang Shun; Chi, Kwan Hwa; Hu, Maw Hwa; Fahn, Huei Jyh; Huang, Min Hsiung.

In: Journal of Surgical Oncology, Vol. 62, No. 1, 05.1996, p. 22-29.

Research output: Contribution to journalArticle

Wang, Liang Shun ; Chi, Kwan Hwa ; Hu, Maw Hwa ; Fahn, Huei Jyh ; Huang, Min Hsiung. / Management for patients with advanced T4 epidermoid carcinoma of the esophagus. In: Journal of Surgical Oncology. 1996 ; Vol. 62, No. 1. pp. 22-29.
@article{ad34ea9b619542239221b5b59a77b0c9,
title = "Management for patients with advanced T4 epidermoid carcinoma of the esophagus",
abstract = "Available data concerning the treatment of patients with advanced T4 esophageal carcinoma are limited. A consecutive series of 42 patients with advanced T4M0 epidermoid carcinoma of the esophagus were studied from June 1987 to July 1992. The aim of this study was to evaluate the efficacy of various therapeutic modalities, and further evaluate the therapeutic options. The various therapeutic modalities included the following: Group 1, feeding jejunostomy or endoesophageal intubation, 6 patients; Group II, palliative subtotal esophagectomy only, 8 patients; Group III, bypass procedures without tumor resection, 9 patients; Group IV, nutritional support and then treatment with irradiation (n = 8) or concurrent radio-chemotherapy (n = 4), 12 patients; Group V, subtotal esophagectomy, followed by aggressive concurrent radiochemotherapy, 7 patients. The total prescribed irradiation dose was 60 Gy (10 Gy/5 fractions/week). A combination regimen of chemotherapy consisted of cisplatin, 5-fluorouracil, and leucovorin (PFL regimen). For the patients undergoing esophagectomy or bypass procedures (n = 24), the rates of operative complication and mortality were 45.8{\%} and 25{\%}, respectively. Side effects of adjuvant therapy (n = 24) consisted of main airway irritation (100{\%}), mucositis or gastrointestinal symptoms (83.3{\%}), hematologic toxicity (79.2{\%}), esophagitis or gastric ulcer (62.5{\%}), alopecia (37.5{\%}), and pneumonia (20.8{\%}). The mortality due to toxicity of adjuvant therapy was 21.1{\%} (4/19 patients). The mean survival times for each of the different groups was 1.9 ± 0.5 months for Group I, 4.8 ± 1.6 months for Group II, 5.2 ± 1.2 months for Group III, 7.3 ± 2.0 months for Group IV, and 20.3 ± 2.5 months for Group V, respectively. Compared with patients of Groups I-IV, the Group V patients had a significantly superior one-year survival rate (P <0.01). Our results demonstrated that esophagectomy followed by concurrent irradiation and PFL combination chemotherapy may provide a significant improvement in the quality of life and survival for appropriate patients with advanced T4M0 epidermoid carcinoma of the esophagus. Furthermore, more than one cycle of PFL regimen chemotherapy may result in a better prognosis. During the performance of such an aggressive treatment, the utmost care must be taken with the patient's nutrition and to prevent pulmonary complications.",
keywords = "esophageal carcinoma, esophagectomy, radiochemotherapy",
author = "Wang, {Liang Shun} and Chi, {Kwan Hwa} and Hu, {Maw Hwa} and Fahn, {Huei Jyh} and Huang, {Min Hsiung}",
year = "1996",
month = "5",
doi = "10.1002/(SICI)1096-9098(199605)62:1<22::AID-JSO5>3.0.CO;2-T",
language = "English",
volume = "62",
pages = "22--29",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Management for patients with advanced T4 epidermoid carcinoma of the esophagus

AU - Wang, Liang Shun

AU - Chi, Kwan Hwa

AU - Hu, Maw Hwa

AU - Fahn, Huei Jyh

AU - Huang, Min Hsiung

PY - 1996/5

Y1 - 1996/5

N2 - Available data concerning the treatment of patients with advanced T4 esophageal carcinoma are limited. A consecutive series of 42 patients with advanced T4M0 epidermoid carcinoma of the esophagus were studied from June 1987 to July 1992. The aim of this study was to evaluate the efficacy of various therapeutic modalities, and further evaluate the therapeutic options. The various therapeutic modalities included the following: Group 1, feeding jejunostomy or endoesophageal intubation, 6 patients; Group II, palliative subtotal esophagectomy only, 8 patients; Group III, bypass procedures without tumor resection, 9 patients; Group IV, nutritional support and then treatment with irradiation (n = 8) or concurrent radio-chemotherapy (n = 4), 12 patients; Group V, subtotal esophagectomy, followed by aggressive concurrent radiochemotherapy, 7 patients. The total prescribed irradiation dose was 60 Gy (10 Gy/5 fractions/week). A combination regimen of chemotherapy consisted of cisplatin, 5-fluorouracil, and leucovorin (PFL regimen). For the patients undergoing esophagectomy or bypass procedures (n = 24), the rates of operative complication and mortality were 45.8% and 25%, respectively. Side effects of adjuvant therapy (n = 24) consisted of main airway irritation (100%), mucositis or gastrointestinal symptoms (83.3%), hematologic toxicity (79.2%), esophagitis or gastric ulcer (62.5%), alopecia (37.5%), and pneumonia (20.8%). The mortality due to toxicity of adjuvant therapy was 21.1% (4/19 patients). The mean survival times for each of the different groups was 1.9 ± 0.5 months for Group I, 4.8 ± 1.6 months for Group II, 5.2 ± 1.2 months for Group III, 7.3 ± 2.0 months for Group IV, and 20.3 ± 2.5 months for Group V, respectively. Compared with patients of Groups I-IV, the Group V patients had a significantly superior one-year survival rate (P <0.01). Our results demonstrated that esophagectomy followed by concurrent irradiation and PFL combination chemotherapy may provide a significant improvement in the quality of life and survival for appropriate patients with advanced T4M0 epidermoid carcinoma of the esophagus. Furthermore, more than one cycle of PFL regimen chemotherapy may result in a better prognosis. During the performance of such an aggressive treatment, the utmost care must be taken with the patient's nutrition and to prevent pulmonary complications.

AB - Available data concerning the treatment of patients with advanced T4 esophageal carcinoma are limited. A consecutive series of 42 patients with advanced T4M0 epidermoid carcinoma of the esophagus were studied from June 1987 to July 1992. The aim of this study was to evaluate the efficacy of various therapeutic modalities, and further evaluate the therapeutic options. The various therapeutic modalities included the following: Group 1, feeding jejunostomy or endoesophageal intubation, 6 patients; Group II, palliative subtotal esophagectomy only, 8 patients; Group III, bypass procedures without tumor resection, 9 patients; Group IV, nutritional support and then treatment with irradiation (n = 8) or concurrent radio-chemotherapy (n = 4), 12 patients; Group V, subtotal esophagectomy, followed by aggressive concurrent radiochemotherapy, 7 patients. The total prescribed irradiation dose was 60 Gy (10 Gy/5 fractions/week). A combination regimen of chemotherapy consisted of cisplatin, 5-fluorouracil, and leucovorin (PFL regimen). For the patients undergoing esophagectomy or bypass procedures (n = 24), the rates of operative complication and mortality were 45.8% and 25%, respectively. Side effects of adjuvant therapy (n = 24) consisted of main airway irritation (100%), mucositis or gastrointestinal symptoms (83.3%), hematologic toxicity (79.2%), esophagitis or gastric ulcer (62.5%), alopecia (37.5%), and pneumonia (20.8%). The mortality due to toxicity of adjuvant therapy was 21.1% (4/19 patients). The mean survival times for each of the different groups was 1.9 ± 0.5 months for Group I, 4.8 ± 1.6 months for Group II, 5.2 ± 1.2 months for Group III, 7.3 ± 2.0 months for Group IV, and 20.3 ± 2.5 months for Group V, respectively. Compared with patients of Groups I-IV, the Group V patients had a significantly superior one-year survival rate (P <0.01). Our results demonstrated that esophagectomy followed by concurrent irradiation and PFL combination chemotherapy may provide a significant improvement in the quality of life and survival for appropriate patients with advanced T4M0 epidermoid carcinoma of the esophagus. Furthermore, more than one cycle of PFL regimen chemotherapy may result in a better prognosis. During the performance of such an aggressive treatment, the utmost care must be taken with the patient's nutrition and to prevent pulmonary complications.

KW - esophageal carcinoma

KW - esophagectomy

KW - radiochemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029863764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029863764&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9098(199605)62:1<22::AID-JSO5>3.0.CO;2-T

DO - 10.1002/(SICI)1096-9098(199605)62:1<22::AID-JSO5>3.0.CO;2-T

M3 - Article

C2 - 8618396

AN - SCOPUS:0029863764

VL - 62

SP - 22

EP - 29

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -